While LENZ Therapeutics Inc. has overperformed by 2.38%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, LENZ rose by 84.94%, with highs and lows ranging from $23.50 to $9.91, whereas the simple moving average jumped by 70.11% in the last 200 days.
On March 27, 2024, Piper Sandler started tracking LENZ Therapeutics Inc. (NASDAQ: LENZ) recommending Overweight. A report published by Cowen on February 23, 2023, Downgraded its rating to ‘Market Perform’ for LENZ. Cantor Fitzgerald also Downgraded LENZ shares as ‘Neutral’, setting a target price of $3 on the company’s shares in a report dated February 23, 2023. BofA Securities February 23, 2023d the rating to Underperform on February 23, 2023, and set its price target from $3 to $2. BTIG Research January 25, 2023d its ‘Buy’ rating to ‘Neutral’ for LENZ, as published in its report on January 25, 2023. BofA Securities’s report from January 18, 2023 suggests a price prediction of $3 for LENZ shares, giving the stock a ‘Neutral’ rating. SVB Leerink also rated the stock as ‘Mkt Perform’.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Analysis of LENZ Therapeutics Inc. (LENZ)
It’s important to note that LENZ shareholders are currently getting $0.00 per share in dividends, so investors will receive a return regardless of how the company performs.
LENZ Therapeutics Inc.’s future performance can be predicted by a variety of well-rounded types of analysis and research, with equity being one of the most crucial ones. The goal here is to ensure that your current return on equity of -51.95% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 39.20, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can be an extremely valuable indicator of volatility, and LENZ is registering an average volume of 61.74K. On a monthly basis, the volatility of the stock is set at 11.59%, whereas on a weekly basis, it is put at 16.88%, with a gain of 0.31% over the past seven days. Furthermore, long-term investors anticipate a median target price of $28.00, showing growth from the present price of $22.33, which can serve as yet another indication of whether LENZ is worth investing in or should be passed over.
How Do You Analyze LENZ Therapeutics Inc. Shares?
Besides checking the fundamentals, you should also know how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 52.59%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 63.01% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
LENZ shares are owned by institutional investors to the tune of 63.01% at present.
